Cagrilintide+semaglutide (CagriSema) is a combination of 2.4 mg of long-acting GLP-1RA semaglutide and amylin analog cagrilintide administered once a week
These results indicate that cagrilintides metabolic effects are receptor-dependent and that functional AMY1R/AMY3R signaling is essential for proper nutrient partitioning and energy balance regulation
However, it has less research behind it overall and is typically used as a complementary peptide alongside GHK-Cu rather than as a standalone treatment
In a 26-week phase 2 trial involving individuals without diabetes, it was evaluated at doses ranging from 0.3 mg to 4.5 mg per week
So let me give you a clear, honest, evidence-based look at what we actually know, what remains uncertain, and what I tell my patients when they ask about it
Available online at: May 4, 2022)